June 29, 2021 09:16 AM EDTUpdated June 30, 04:30 AM

FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report

Josh Sullivan

Top FDA neuroscience official Billy Dunn has been a vocal advocate for Biogen and its Alzheimer’s drug Aduhelm throughout the entire review process all the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report

Josh Sullivan

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

FDA and Bio­gen dis­cussed Aduhelm's ac­cel­er­at­ed ap­proval as ear­ly as 2019 — re­port

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA and Biogen discussed Aduhelm's accelerated approval as early as 2019 — report